BioPharma Credit

Name

BioPharma Credit

Legal name

BioPharma Credit PLC

Website

https://bpcruk.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Life Sciences Debt Financing

NAICS

Credit Intermediation and Related Activities (522)

SIC

Miscellaneous Business Credit Institution (6159)

akta.pro primary industry

Private Credit / Direct Lending (FSAAAHAG)

akta.pro secondary industry

Specialty Finance / Structured Credit (FSANADAE)

Keywords

• Life sciences debt financing
• Royalty monetization loans
• Senior secured biotech lending
• Pharmaceutical credit facility
• Specialty healthcare lending

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Interest Income from Loans: BioPharma Credit generates revenue primarily through interest income from its portfolio of senior secured loans and other debt instruments provided to life sciences companies. The loans have fixed interest rates and maturity dates, with earnings from interest and milestones.
2. Dividend Distribution: The company pays quarterly dividends to shareholders from interest income and other investment returns. The base annual dividend target is 7 cents per share, distributed in four quarterly payments. The entire dividend is designated as an interest distribution for UK tax purposes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BioPharma Credit PLC is a London-listed closed-end investment company that provides debt capital to biotechnology and pharmaceutical companies globally. Its loan products include senior secured loans, royalty debt instruments, priority royalty tranches, credit linked notes, and unsecured debt, collateralized by Royalty Collateral, intellectual property, and marketing rights of life sciences borrowers. The company is externally managed by Pharmakon Advisors, LP and earns interest income and milestone payments that are distributed as quarterly dividends to public shareholders.

Product overview

BioPharma Credit PLC is a single, unified investment company listed on the London Stock Exchange. It operates as a closed-end investment trust providing debt financing products to the life sciences industry. The company's primary offering consists of senior secured loans, royalty monetization structures, and other debt instruments extended to biotech and pharmaceutical companies. The investment strategy is managed by Pharmakon Advisors, LP, with the objective of generating predictable income for shareholders through interest distributions from its loan portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• Senior Secured Loans Debt issued by life sciences companies secured as to repayment of principal and/or payment of interest by a first priority charge over some or all of the borrower's assets, including Royalty Collateral, intellectual property, and marketing rights. The loans have fixed interest rates and maturity dates, with earnings from interest and milestones (e.g., up to CHF 75 million loan to Idorsia Pharmaceuticals Ltd maturing June 2031; $250 million loan facility to Geron Corporation).
• Royalty Debt Instruments (including RPS Note) Debt issued by a Royalty Owner where obligations are secured by Royalty Collateral, including the RPS Note. Provides biopharmaceutical companies with non-dilutive financing by monetizing future royalty streams from their products.
• Priority Royalty Tranches Contract with a Borrower providing the right to receive payment of all or a fixed percentage of future royalty payments up to a fixed monetary amount or pre-set rate of return, secured by Royalty Collateral. Enables structured prioritization of royalty cash flows for lenders.
• Credit Linked Notes Derivative instruments referencing Debt Assets, being a synthetic obligation between the Company and another party where repayment is based on the performance of obligations under underlying Debt Assets.
• Unsecured Debt Debt instruments issued to life sciences companies without specific asset collateralization, offered as part of BioPharma Credit's broader debt financing portfolio to biotechnology and pharmaceutical companies globally.

Quantifiable outcome

• 89 clinical trials being funded by partners as at December 2024
• +3 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators14 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• OrbiMed: OrbiMed is a leading healthcare-dedicated investment firm across private equity, credit, and royalties. Its private credit arm directly competes with BioPharma Credit for life sciences debt and royalty opportunities.
• Innovatus Capital Partners: Innovatus manages life sciences-focused credit strategies, including direct lending and royalty financing to biotech and specialty pharma companies. Comparable in asset class focus and borrower profile.
• HealthCare Royalty Partners: HCR is a dedicated healthcare royalty and credit investment firm. Comparable to BioPharma Credit in providing royalty monetization and structured debt to biotech and pharmaceutical companies, with overlapping borrower relationships.
• Royalty Pharma: Royalty Pharma is the largest dedicated life sciences royalty buyer globally, providing capital against future royalty streams. Directly comparable to BioPharma Credit's royalty debt instruments and priority royalty tranches, though with a much larger balance sheet and broader mandate.
• K2 HealthVentures: K2 HealthVentures provides debt financing to life sciences companies, including venture debt and structured loans. Operates in the same healthcare specialty lending niche as BioPharma Credit.
• SWK Holdings: SWK Holdings is a publicly traded specialty finance company focused exclusively on life sciences, providing debt and royalty financing to biotech and pharma. Operates in the same niche as BioPharma Credit with similar senior secured and royalty loan structures.

Others

• BridgeBio Pharma: BridgeBio is a clinical-stage biotech focused on genetic disease therapies. While not a financing peer, it represents the type of clinical-stage borrower that BioPharma Credit finances — and BPC's loan portfolio includes similar counterparties.
• Pharmakon Advisors: Pharmakon Advisors is the investment manager of BioPharma Credit's funds. While not a comparable peer, it represents the closest aligned capital pool — managing BioPharma Credit's portfolio of life sciences debt.

Emerging players

• Perceptive Advisors: Perceptive Advisors manages life sciences-focused credit and equity strategies. While broader than BioPharma Credit, its credit activities compete directly for healthcare structured finance opportunities.

Broad incumbents

• Hercules Capital: Hercules Capital is the largest publicly traded venture debt provider, including a significant life sciences lending practice. Broader than BioPharma Credit in sector coverage but directly comparable in providing senior secured loans to biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmakon-advisors-lp

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioPharma Credit